18/03/2026 Idience's venadaparib received the FDA fast track designation for gastric cancer Idience's venadaparib received the FDA fast track designation for gastric cancer ( Ref ) The US FDA granted the fast track designation to Idience's venadaparib (PARP inhibitor) for the treatment of gastric cancer. Lee Won-sik, CEO, Idience: “ This Fast Track designation is highly meaningful in that the FDA has recognized Venadaparib’s clinical potential and its ability to help address